CORDIS
EU research results

CORDIS

English EN

Educational Network in Ocular Drug Delivery and Therapeutics

Project information

Grant agreement ID: 722717

Status

Ongoing project

  • Start date

    1 November 2016

  • End date

    31 October 2020

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 933 728,88

  • EU contribution

    € 3 933 728,88

Coordinated by:

ITA-SUOMEN YLIOPISTO

Finland

Objective

Ocular drug development has transformed from niche area to a major field in drug development in which many companies, including European big pharma has entered recently. Ocular drug development is a unique field in terms of drug targets and end-points of activity, local drug administration routes, tissue barriers and pharmacokinetics, drug delivery and formulation challenges and local toxicity issues. These issues are slowing down the development of drugs for the unmet needs in ophthalmology. The main objective of the proposal is to educate experts of preclinical ocular R&D to facilitate the success of European pharmaceutical industry and research community. This objective will be reached by joining forces of the leading European academic and industrial researchers in ophthalmology, materials science and nanomedicine, drug delivery and targeting, and systems pharmacology. We shall educate 15 Early Stage Researchers in a network where they will receive tailored, multi-disciplinary and inter-sectoral education in preclinical ocular drug development. The thesis projects are directed to the drug treatment of retinal diseases, the major challenge in the field. The proposal combines new drug candidates from the experts of ophthalmology, innovative drug delivery technologies from pharmaceutical scientists and companies, and modern in vitro, in silico and in vivo methods from various partners. The thesis projects include secondments in academic and industrial partner laboratories and course programme that encompasses the relevant fields in ocular drug development. Therefore, this proposal presents unique combination of innovation and education in the field with obvious need for such education. The ESRs and other outcomes of this project will greatly benefit the future competitiveness of European science and industry in this field of expanding importance.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ITA-SUOMEN YLIOPISTO

Address

Yliopistonranta 1 E
70211 Kuopio

Finland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 807 436,08

Participants (8)

EBERHARD KARLS UNIVERSITAET TUEBINGEN

Germany

EU Contribution

€ 373 824,72

THE QUEEN'S UNIVERSITY OF BELFAST

United Kingdom

EU Contribution

€ 546 575,76

UNIVERSITE DE STRASBOURG

France

EU Contribution

€ 262 875,60

TECHNISCHE UNIVERSITEIT EINDHOVEN

Netherlands

EU Contribution

€ 255 374,28

UNIVERSITA DEGLI STUDI DI PADOVA

Italy

EU Contribution

€ 516 122,64

UNIVERSITEIT UTRECHT

Netherlands

EU Contribution

€ 635 356,32

OZ BIOSCIENCES SAS

France

EU Contribution

€ 262 875,60

CERTARA UK LIMITED

United Kingdom

EU Contribution

€ 273 287,88

Partners (9)

BAYER AKTIENGESELLSCHAFT

Germany

20MED THERAPEUTICS BV

Netherlands

Retina International

Switzerland

SLASKI UNIWERSYTET MEDYCZNY W KATOWICACH

Poland

UNIVERSIDAD COMPLUTENSE DE MADRID

Spain

DELSITECH OY

Finland

Bio-Ker s.r.l

Italy

Vasgen ltd

United Kingdom

INNOCORE TECHNOLOGIES BV

Netherlands

Project information

Grant agreement ID: 722717

Status

Ongoing project

  • Start date

    1 November 2016

  • End date

    31 October 2020

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 933 728,88

  • EU contribution

    € 3 933 728,88

Coordinated by:

ITA-SUOMEN YLIOPISTO

Finland